BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 27474148)

  • 1. Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC.
    Liu X; Jiang Y; Nowak B; Hargis S; Plunkett W
    Mol Cancer Ther; 2016 Oct; 15(10):2302-2313. PubMed ID: 27474148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.
    Liu X; Jiang Y; Nowak B; Qiang B; Cheng N; Chen Y; Plunkett W
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):255-267. PubMed ID: 29189915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
    Liu XJ; Nowak B; Wang YQ; Plunkett W
    Chin J Cancer; 2012 Aug; 31(8):373-80. PubMed ID: 22739266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors.
    Al Abo M; Sasanuma H; Liu X; Rajapakse VN; Huang SY; Kiselev E; Takeda S; Plunkett W; Pommier Y
    Mol Cancer Ther; 2017 Nov; 16(11):2543-2551. PubMed ID: 28802254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repair of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine-induced DNA single-strand breaks by transcription-coupled nucleotide excision repair.
    Wang Y; Liu X; Matsuda A; Plunkett W
    Cancer Res; 2008 May; 68(10):3881-9. PubMed ID: 18483273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC.
    Liu X; Wang Y; Benaissa S; Matsuda A; Kantarjian H; Estrov Z; Plunkett W
    Blood; 2010 Sep; 116(10):1737-46. PubMed ID: 20479284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
    Hanaoka K; Suzuki M; Kobayashi T; Tanzawa F; Tanaka K; Shibayama T; Miura S; Ikeda T; Iwabuchi H; Nakagawa A; Mitsuhashi Y; Hisaoka M; Kaneko M; Tomida A; Wataya Y; Nomura T; Sasaki T; Matsuda A; Tsuruo T; Kurakata S
    Int J Cancer; 1999 Jul; 82(2):226-36. PubMed ID: 10389757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
    Liu X; Guo Y; Li Y; Jiang Y; Chubb S; Azuma A; Huang P; Matsuda A; Hittelman W; Plunkett W
    Cancer Res; 2005 Aug; 65(15):6874-81. PubMed ID: 16061671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine.
    Liu X; Matsuda A; Plunkett W
    Mol Cancer Ther; 2008 Jan; 7(1):133-42. PubMed ID: 18202016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sapacitabine for cancer.
    Liu X; Kantarjian H; Plunkett W
    Expert Opin Investig Drugs; 2012 Apr; 21(4):541-55. PubMed ID: 22329458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repair of DNA damage induced by the novel nucleoside analogue CNDAG through homologous recombination.
    Liu X; Jiang Y; Nowak B; Ichikawa S; Ohtawa M; Matsuda A; Plunkett W
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):661-672. PubMed ID: 32072218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleosides and nucleotides. 141. Chemical stability of a new antitumor nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine in alkaline medium: formation of 2'-C-cyano-2'-deoxy-1-beta-D-ribo-pentofuranosylcytosine and its antitumor activity.
    Azuma A; Hanaoka K; Kurihara A; Kobayashi T; Miyauchi S; Kamo N; Tanaka M; Sasaki T; Matsuda A
    J Med Chem; 1995 Aug; 38(17):3391-7. PubMed ID: 7650692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.
    Azuma A; Huang P; Matsuda A; Plunkett W
    Mol Pharmacol; 2001 Apr; 59(4):725-31. PubMed ID: 11259616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.
    Curtin NJ; Wang LZ; Yiakouvaki A; Kyle S; Arris CA; Canan-Koch S; Webber SE; Durkacz BW; Calvert HA; Hostomsky Z; Newell DR
    Clin Cancer Res; 2004 Feb; 10(3):881-9. PubMed ID: 14871963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC).
    Azuma A; Huang P; Matsuda A; Plunkett W
    Biochem Pharmacol; 2001 Jun; 61(12):1497-507. PubMed ID: 11377379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
    Serova M; Galmarini CM; Ghoul A; Benhadji K; Green SR; Chiao J; Faivre S; Cvitkovic E; Le Tourneau C; Calvo F; Raymond E
    Br J Cancer; 2007 Sep; 97(5):628-36. PubMed ID: 17637678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.
    Liu L; Taverna P; Whitacre CM; Chatterjee S; Gerson SL
    Clin Cancer Res; 1999 Oct; 5(10):2908-17. PubMed ID: 10537360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Design of a new antitumor nucleoside CNDAC, against solid tumors].
    Matsuda A
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):202-10. PubMed ID: 8611048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside.
    Matsuda A; Nakajima Y; Azuma A; Tanaka M; Sasaki T
    J Med Chem; 1991 Sep; 34(9):2917-9. PubMed ID: 1895307
    [No Abstract]   [Full Text] [Related]  

  • 20. Development and biochemical characterization of a 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC)-resistant variant of the human fibrosarcoma cell line HT-1080.
    Obata T; Endo Y; Tanaka M; Matsuda A; Sasaki T
    Cancer Lett; 1998 Jan; 123(1):53-61. PubMed ID: 9461018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.